Who is moving to which position
Resolved 4 September 2026 (the filing states that the personnel changes were decided)To achieve “ASKA VISION 2035” and “Medium-Term Management Plan 2028,” the first 3-year implementation plan toward achieving that vision, the pharmaceutical business and administrative functions will be reorganized. Through this reorganization, the company aims to strengthen its management platform for sustainable growth by clarifying the allocation of authority and responsibility, strengthening coordination between divisions and enabling agile decision-making.
A new Pharmaceutical Business Management organization will be established at the same level as the headquarters organizations. The Medical Affairs Department, currently under the Sales Headquarters, Endocrine Business Promotion Office and Business Development Headquarters, will be transferred to the Pharmaceutical Business Management organization. The Business Strategy Promotion Office will be abolished. The Corporate Planning Department will be abolished, and a new Corporate Strategy Headquarters will be established, with a Corporate Strategy Office and a Business Promotion Department under it. A new Legal Department will be established under the Administration Headquarters.
| Item | Details |
|---|---|
| Resolution date | 4 September 2026 (the filing states that the personnel changes were decided) |
| Scheduled Appointment Date | Scheduled appointment date |
| Reason for change | To achieve “ASKA VISION 2035” and “Medium-Term Management Plan 2028,” the first 3-year implementation plan toward achieving that vision, the pharmaceutical business and administrative functions will be reorganized. Through this reorganization, the company aims to strengthen its management platform for sustainable growth by clarifying the allocation of authority and responsibility, strengthening coordination between divisions and enabling agile decision-making. |
| Number of directors after the change | 6; number of outside directors: Not disclosed |
| Details of organizational changes | A new Pharmaceutical Business Management organization will be established at the same level as the headquarters organizations. The Medical Affairs Department, currently under the Sales Headquarters, Endocrine Business Promotion Office and Business Development Headquarters, will be transferred to the Pharmaceutical Business Management organization. The Business Strategy Promotion Office will be abolished. The Corporate Planning Department will be abolished, and a new Corporate Strategy Headquarters will be established, with a Corporate Strategy Office and a Business Promotion Department under it. A new Legal Department will be established under the Administration Headquarters. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To achieve “ASKA VISION 2035” and “Medium-Term Management Plan 2028,” the pharmaceutical business and administrative functions will be reorganized. The company aims to strengthen its management platform for sustainable growth by clarifying the allocation of authority and responsibility, strengthening coordination between divisions and enabling agile decision-making.